FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028656867> ?p ?o ?g. }

• W2028656867 endingPage "20028" @default.
• W2028656867 startingPage "20022" @default.
• W2028656867 abstract "Here we show that in human T-cell leukemia cells Vav1 and protein kinase C θ (PKCθ) synergize for the activation of c-Jun N-terminal kinase (JNK) but not p38 MAP kinase. Vav1 and PKCθ also cooperated to induce transcription of reporter genes controlled either by AP-1 binding sites or the CD28RE/AP composite element contained in the IL-2 promoter by stimulating the binding of transcription factors to these two elements. Dominant negative versions of Vav1 and PKCθ inhibited CD3/CD28-induced activation of JNK, revealing their relative importance for this activation pathway. Gel filtration experiments revealed the existence of constitutively associated Vav1/PKCθ heterodimers in extracts from unstimulated T-cells, whereas T-cell costimulation induced the recruitment of Vav1 into high molecular weight complexes. Several experimental approaches showed that Vav1 is located upstream from PKCθ in the control of the pathway leading to synergistic JNK activation. Vav1-derived signals lead to the activation of JNK by at least two different pathways. The major contribution of Vav1 for the activation of JNK relies on the PKCθ-mediated Ca2+-independent synergistic activation pathway, whereas JNK is also activated by a separate Ca2+-dependent signaling route. Here we show that in human T-cell leukemia cells Vav1 and protein kinase C θ (PKCθ) synergize for the activation of c-Jun N-terminal kinase (JNK) but not p38 MAP kinase. Vav1 and PKCθ also cooperated to induce transcription of reporter genes controlled either by AP-1 binding sites or the CD28RE/AP composite element contained in the IL-2 promoter by stimulating the binding of transcription factors to these two elements. Dominant negative versions of Vav1 and PKCθ inhibited CD3/CD28-induced activation of JNK, revealing their relative importance for this activation pathway. Gel filtration experiments revealed the existence of constitutively associated Vav1/PKCθ heterodimers in extracts from unstimulated T-cells, whereas T-cell costimulation induced the recruitment of Vav1 into high molecular weight complexes. Several experimental approaches showed that Vav1 is located upstream from PKCθ in the control of the pathway leading to synergistic JNK activation. Vav1-derived signals lead to the activation of JNK by at least two different pathways. The major contribution of Vav1 for the activation of JNK relies on the PKCθ-mediated Ca2+-independent synergistic activation pathway, whereas JNK is also activated by a separate Ca2+-dependent signaling route. c-Jun N-terminal kinase nuclear factor-κB interleukin protein kinase C JNK kinase dominant negative electrophoretic mobility shift assay hemagglutinin glutathione S-transferase Activation of the T-cell antigen receptor complex is not sufficient for T-lymphocyte activation and requires additional signals provided by the occupancy of costimulatory receptors such as CD28 (1Schwartz R.H. Curr. Opin. Immunol. 1997; 9: 351-357Crossref PubMed Scopus (228) Google Scholar). Full activation of T-cells by T-cell antigen receptor/CD28 costimulation initiates a series of intracellular signaling events. A hallmark of costimulated T-cells is the synergistic activation of JNK,1 NF-κB, and IL-2 expression (2Jung S. Yaron A. Alkalay I. Hatzubai A. Avraham A. Ben-Neriah Y. Ann. N. Y. Acad. Sci. 1995; 766: 245-252Crossref PubMed Scopus (32) Google Scholar). Receptor clustering leads to the activation of protein tyrosine kinases of the Src and Syk families, which phosphorylate numerous substrate proteins, thus leading to dynamic formation (3Myung P.S. Boerthe N.J. Koretzky G.A. Curr. Opin. Immunol. 2000; 12: 256-266Crossref PubMed Scopus (94) Google Scholar) or disruption (4Dienz O. Hehner S.P. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 24547-24551Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar) of multi-protein signaling complexes. These complexes and the T-cell antigen receptor itself associate with lipid rafts, which form a structural scaffold and promote further signaling events (5Janes P.W. Ley S.C. Magee A.I. Kabouridis P.S. Semin. Immunol. 2000; 12: 23-34Crossref PubMed Scopus (361) Google Scholar). Activated protein tyrosine kinases phosphorylate multiple target proteins including phospholipase Cγ, which controls the phosphatidyl inositol lipid metabolism, thereby producing inositol triphosphate and diacylglycerols (6Cantrell D. Annu. Rev. Immunol. 1996; 14: 259-274Crossref PubMed Scopus (593) Google Scholar). Whereas inositol triphosphate results in a rapid and sustained calcium increase, diacylglycerol mediates activation of PKC family members (6Cantrell D. Annu. Rev. Immunol. 1996; 14: 259-274Crossref PubMed Scopus (593) Google Scholar, 7Berridge M.J. Crit. Rev. Immunol. 1997; 17: 155-178Crossref PubMed Google Scholar). Among those, the novel Ca2+-independent PKC isoform PKCθ is of special importance for T-cells, because it is rapidly recruited to the site of contact between T-cells and antigen-presenting cells (8Monks C.R. Kupfer H. Tamir I. Barlow A. Kupfer A. Nature. 1997; 385: 83-86Crossref PubMed Scopus (491) Google Scholar). Another protein tyrosine kinase-induced signaling route is mediated by the Vav1 protein family member Vav1, which is exclusively expressed in hematopoietic cells (9Bustelo X.R. Mol. Cell. Biol. 2000; 20: 1461-1477Crossref PubMed Scopus (446) Google Scholar). T-cell costimulation induces the membrane recruitment of Vav1 via indirect, adaptor protein SLP-76-mediated binding to the membrane protein LAT (linker for activation of T-cells) (10Hehner S.P. Hofmann T.G. Dienz O. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar). Protein tyrosine kinase-induced phosphorylation and phosphatidylinositol-3,4,5-triphosphate binding of Vav1 activate its GDP/GTP exchange factor activity for the Rho family of GTPases such as Rac and Cdc42 (11Crespo P. Schuebel K.E. Ostrom A.A. Gutkind J.S. Bustelo X.R. Nature. 1997; 385: 169-172Crossref PubMed Scopus (680) Google Scholar, 12Han J. Luby-Phelps K. Das B. Shu X. Xia Y. Mosteller R.D. Krishna U.M. Falck J.R. White M.A. Broek D. Science. 1998; 279: 558-560Crossref PubMed Scopus (710) Google Scholar) and results in the stimulation of signaling pathways and alterations in cell shape and motility. T-cell costimulation also leads to the activation of mitogen-activated protein kinase pathways. However, the synergistic activation appears to be unique for the mitogen-activated protein kinases JNK and p38 (13Salojin K.V. Zhang J. Delovitch T.L. J. Immunol. 1999; 163: 844-853PubMed Google Scholar), because neither extracellular signal-regulated kinase nor transcription factor nuclear factor of activated T-cells require coreceptor-derived signals. JNK phosphorylates various transcription factors including ATF2, ELK-1, and components of the AP-1 heterodimer, namely JunB, JunD, and c-Jun (14Davis R.J. Cell. 2000; 103: 239-252Abstract Full Text Full Text PDF PubMed Scopus (3626) Google Scholar). Because AP-1 contributes to the induced expression of numerous target genes including IL-2and IL-4, the JNK pathway has been implicated in various functions including cell proliferation, effector T-cell function (15Dong C. Yang D.D. Tournier C. Whitmarsh A.J. Xu J. Davis R.J. Flavell R.A. Nature. 2000; 405: 91-94Crossref PubMed Scopus (284) Google Scholar), T-cell activation (16Sabapathy K. Hu Y. Kallunki T. Schreiber M. David J.P. Jochum W. Wagner E.F. Karin M. Curr. Biol. 1999; 9: 116-125Abstract Full Text Full Text PDF PubMed Scopus (271) Google Scholar), and the regulation of apoptosis (14Davis R.J. Cell. 2000; 103: 239-252Abstract Full Text Full Text PDF PubMed Scopus (3626) Google Scholar). However, these functions are dependent on the inducing signal and the cell type (15Dong C. Yang D.D. Tournier C. Whitmarsh A.J. Xu J. Davis R.J. Flavell R.A. Nature. 2000; 405: 91-94Crossref PubMed Scopus (284) Google Scholar, 16Sabapathy K. Hu Y. Kallunki T. Schreiber M. David J.P. Jochum W. Wagner E.F. Karin M. Curr. Biol. 1999; 9: 116-125Abstract Full Text Full Text PDF PubMed Scopus (271) Google Scholar). JNK is activated by the dual specificity JNK kinases (JNKKs) MKK4/JNKK1/SEK1 and JNKK2/MKK7 (17Ichijo H. Oncogene. 1999; 18: 6087-6093Crossref PubMed Scopus (472) Google Scholar). A variety of different kinases can activate the JNKKs, but the cell type and the nature of the JNK-inducing stimulus determines which of these kinases is operational (14Davis R.J. Cell. 2000; 103: 239-252Abstract Full Text Full Text PDF PubMed Scopus (3626) Google Scholar). Vav1 and PKCθ are constitutively associated in unstimulated T-cells (18Kong Y.Y. Fischer K.D. Bachmann M.F. Mariathasan S. Kozieradzki I. Nghiem M.P. Bouchard D. Bernstein A. Ohashi P.S. Penninger J.M. J. Exp. Med. 1998; 188: 2099-2111Crossref PubMed Scopus (84) Google Scholar), and both proteins synergistically activate transcription factor NF-κB, JNK activity, and the expression of IL-2, CD69, and IL-4 (4Dienz O. Hehner S.P. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 24547-24551Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar,19Hehner S.P. Li-Weber M. Giaisi M. Dröge W. Krammer P.H. Schmitz M.L. J. Immunol. 2000; 164: 3829-3836Crossref PubMed Scopus (54) Google Scholar, 20Villalba M. Coudronniere N. Deckert M. Teixero E. Mas P. Altman A. Immunity. 2000; 12: 151-160Abstract Full Text Full Text PDF PubMed Scopus (199) Google Scholar). In this study we have addressed the question whether Vav1 and PKCθ synergize for the activation of JNK for two reasons. 1) Gain-of-function approaches have revealed that both proteins contribute to the activation of JNK (10Hehner S.P. Hofmann T.G. Dienz O. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar, 21Avraham A. Jung S. Samuels Y. Seger R. Ben-Neriah Y. Eur. J. Immunol. 1998; 28: 2320-2330Crossref PubMed Scopus (70) Google Scholar, 22Werlen G. Jacinto E. Xia Y. Karin M. EMBO J. 1998; 17: 3101-3111Crossref PubMed Scopus (252) Google Scholar, 23Ghaffari-Tabrizi N. Bauer B. Villunger A. Baier-Bitterlich G. Altman A. Utermann G. Uberall F. Baier G. Eur. J. Immunol. 1999; 29: 132-142Crossref PubMed Scopus (108) Google Scholar, 24Arudchandran R. Brown M.J. Peirce M.J. Song J.S. Zhang J. Siraganian R.P. Blank U. Rivera J. J. Exp. Med. 2000; 191: 47-60Crossref PubMed Scopus (74) Google Scholar, 25Miranti C.K. Leng L. Maschberger P. Brugge J.S. Shattil S.J. Curr. Biol. 1998; 8: 1289-1299Abstract Full Text Full Text PDF PubMed Scopus (173) Google Scholar, 26Song J.S. Haleem-Smith H. Arudchandran R. Gomez J. Scott P.M. Mill J.F. Tan T.H. Rivera J. J. Immunol. 1999; 163: 802-810PubMed Google Scholar) and cooperate with constitutively active calcineurin or Ca2+ signals to activate JNK. 2) We have previously seen that the Vav1/PKCθ module synergistically triggers binding of transcription factors to the P1 and PRE-I elements contained within the IL-4 promoter (19Hehner S.P. Li-Weber M. Giaisi M. Dröge W. Krammer P.H. Schmitz M.L. J. Immunol. 2000; 164: 3829-3836Crossref PubMed Scopus (54) Google Scholar). Because both DNA elements are bound by AP-1 family members, we tested the effects of Vav1 and PKCθ on the activation of JNK. A variety of experimental approaches revealed cooperative activation of JNK and AP-1-dependent gene expression by Vav1 and PKCθ. Jurkat T leukemia cells expressing the large T antigen were grown in RPMI 1640 medium at 37 °C containing 10% (v/v) heat-inactivated fetal calf serum, 10 mm HEPES, 1% (v/v) penicillin/streptomycin, 2 mg/ml G418, and 2 mm glutamine (all from Life Technologies, Inc.). Cells were electroporated using a gene pulser (Bio-Rad) at 250 V/950 microfarads. In all transfections, the amount of total DNA (20 μg) was kept constant by the addition of empty expression vector. Stimulations were performed in a volume of 400 μl by adding agonistic αCD3 (final concentration of 10 μg/ml) and/or αCD28 (final concentration of 10 μg/ml) antibodies. The following antibodies were obtained from the indicated suppliers: αPhospho-p38, New England Biolabs; αFlag (M2), Sigma; αMyc (9E10), Santa Cruz Biotechnology, Inc.; αVav1, Upstate Biotechnology; αPKCθ, Transduction Laboratories; αHA antibody (12CA5), Roche Molecular Biochemicals. The αCD3 (OKT3), αCD28 (9.3), and isotype-matched control antibodies were kindly provided by Dr. R. Breitkreutz. The luciferase constructs (AP-1)3-Luc (10Hehner S.P. Hofmann T.G. Dienz O. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar), RE/AP-Luc, and mutant derivatives thereof (27Shapiro V.S. Truitt K.E. Imboden J.B. Weiss A. Mol. Cell. Biol. 1997; 17: 4051-4058Crossref PubMed Scopus (178) Google Scholar) and expression vectors for myc-tagged Vav1 wild type (27Shapiro V.S. Truitt K.E. Imboden J.B. Weiss A. Mol. Cell. Biol. 1997; 17: 4051-4058Crossref PubMed Scopus (178) Google Scholar), Flag-tagged Vav1 wild type and DN Vav1 variants (10Hehner S.P. Hofmann T.G. Dienz O. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar), Flag-tagged p38 (28Raingeaud J. Gupta S. Rogers J.S. Dickens M. Han J. Ulevitch R.J. Davis R.J. J. Biol. Chem. 1995; 270: 7420-7426Abstract Full Text Full Text PDF PubMed Scopus (2040) Google Scholar), PKCθ A/E, PKCθ K/R (19Hehner S.P. Li-Weber M. Giaisi M. Dröge W. Krammer P.H. Schmitz M.L. J. Immunol. 2000; 164: 3829-3836Crossref PubMed Scopus (54) Google Scholar), MKK7 K/L (10Hehner S.P. Hofmann T.G. Dienz O. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar), MEKK1Δ K/M (29Coso O.A. Chiariello M., Yu, J.C. Teramoto H. Crespo P. Xu N. Miki T. Gutkind J.S. Cell. 1995; 81: 1137-1146Abstract Full Text PDF PubMed Scopus (1564) Google Scholar), and MKK4 K/R (30Derijard B. Raingeaud J. Barrett T. Wu I.H. Han J. Ulevitch R.J. Davis R.J. Science. 1995; 267: 682-685Crossref PubMed Scopus (1409) Google Scholar) have been described. EMSAs were performed using nuclear extracts essentially as described (19Hehner S.P. Li-Weber M. Giaisi M. Dröge W. Krammer P.H. Schmitz M.L. J. Immunol. 2000; 164: 3829-3836Crossref PubMed Scopus (54) Google Scholar). Equal amounts of nuclear protein were tested for protein binding to oligonucleotides containing either an AP-1 binding site or a CD28RE/AP element. The coding strands of the oligonucleotides used were as follows: AP-1, 5′-CGCTTGATGACTCAGCCGGAA-3′; CD28RE/AP, 5′-TCTGGTTTAAAGAAATTCCAAAGAGTCATCAG-3′. The free and the oligonucleotide-bound proteins were separated by electrophoresis on a native 4% polyacrylamide gel. Following electrophoresis the gel was dried and exposed to an x-ray film (Amersham Hyperfilm). Luciferase activity in cell extracts was measured in a luminometer (Duo Lumat LB 9507, Berthold) by automatically injecting 50 μl of assay buffer and measuring light emission for 10 s after injection according to the instructions of the manufacturer (Promega Inc.). To ensure comparable transfection efficiencies, results were normalized to β-galactosidase produced by a cotransfected Rous sarcoma virus-β-galactosidase expression vector. Cells were washed with phosphate-buffered saline, and the pellets were resuspended on ice for 15 min in Nonidet P-40 lysis buffer (20 mm Tris/HCl, pH 7.5, 150 mm NaCl, 1 mm phenylmethylsulfonyl fluoride, 10 mm NaF, 0.5 mm sodium vanadate, leupeptin (10 μg/ml), aprotinin (10 μg/ml), 1% (v/v) Nonidet P-40, and 10% (v/v) glycerol). Cell debris was pelleted upon centrifugation, and the supernatant was either directly analyzed by Western blotting or used for the determination of JNK activity as described below. After separation of cell extracts on reducing SDS-polyacrylamide gels, the proteins were transferred onto a polyvinylidene difluoride membrane (Millipore) using a semi-dry blotting apparatus (Bio-Rad). The membrane was then incubated in a small volume of TBST buffer (25 mm Tris/HCl, pH 7.4, 137 nm NaCl, 5 mm KCl, 0.7 mmCaCl2, 0.1 mm MgCl2, 0.1% (v/v) Tween 20) containing various dilutions of the primary antibodies. After extensively washing the membrane, the immunoreactive bands were visualized by enhanced chemiluminescence according to the instructions of the manufacturer (PerkinElmer Life Sciences). Western blots were quantitated using the Lumi-ImagerTM from Roche Molecular Biochemicals. Two days posttransfection, cell lysates were prepared and precleared with protein A/G-Sepharose. The HA-tagged JNK proteins contained in the cell lysate were precipitated by the addition of 1 μg of αHA antibody and 25 μl of protein A/G-Sepharose. The precipitate was washed three times in lysis buffer and two times in kinase buffer (20 mm Hepes/KOH, pH 7.4, 25 mmβ-glycerophosphate, 2 mm dithiothreitol, 20 mm MgCl2). The kinase assay was performed in a final volume of 20 μl of kinase buffer containing 2 μg of glutathione S-transferase (GST)-c-Jun-(5–89), 20 μm ATP, and 5 μCi of [γ-32P]ATP for 20 min at 30 °C. The reaction was stopped by the addition of 5× SDS loading buffer, followed by reducing SDS-PAGE, gel fixation, and quantification of the results in a PhosphorImager. The analysis of cellular multi-protein complexes was performed on a Superose 6 column (Amersham Pharmacia Biotech). Total cell extracts from 3 × 108Jurkat cells contained in 75 μl of octylglycoside lysis buffer (20 mm Tris/HCl, pH 7.5, 150 mm NaCl, 1 mm phenylmethylsulfonyl fluoride, 5 mmdithiothreitol, leupeptin (10 μg/ml), aprotinin (10 μg/ml), 1% (v/v) octylglycoside, and 10% (v/v) glycerol) were analyzed at a flow rate of 0.5 ml/min, and fractions of 500 μl were collected. Aliquots from the respective fractions were analyzed by Western blotting for the occurrence of Vav1 and PKCθ. The washed columns were calibrated with pre-made molecular weight standards (Amersham Pharmacia Biotech). A possible synergism between Vav1 and PKCθ for the activation of JNK was tested by transfecting T-cell leukemia Jurkat cells with expression vectors for HA-tagged JNK together with vectors encoding constitutively active PKCθ (PKCθ A/E) and/or wild type Vav1. The tagged JNK protein was immunoprecipitated, and its kinase activity was determined by immune complex kinase assays (Fig.1 A). JNK activation triggered by expression of Vav1 and PKCθ alone was synergistically stimulated upon coexpression of both proteins. Costimulation with agonistic αCD3/αCD28 antibodies further triggered JNK activity elicited by Vav1, PKCθ A/E, or both. To determine whether the synergy between Vav1 and PKCθ also occurs for the activation of p38, Jurkat T-cells were cotransfected with expression vectors for Flag-tagged p38 together with different combinations of vectors encoding Vav1 and PKCθ A/E. The tagged p38 protein was immunoprecipitated and analyzed for its activation (as seen by Thr-180/Tyr-182 phosphorylation) in Western blot experiments (Fig. 1 B). These experiments showed that Vav1 and PKCθ activated p38 only in an additive, non-synergistic manner, thereby revealing that the cooperation only occurs for the activation of JNK. To test whether this synergism is also apparent at the level of induced AP-1 binding to its cognate DNA, different combinations of expression vectors for Vav1, PKCθ A/E, or the empty expression vector as a control were expressed in Jurkat cells. Analysis of AP-1 DNA binding activity by EMSAs showed that either Vav1 or PKCθ A/E alone induced DNA binding of AP-1, albeit to different extents. Coexpression of both proteins synergistically stimulated the DNA binding activity of AP-1 (Fig.2 B). The impact of Vav1/PKCθ expression on the activation of AP-1-dependent transcription was tested in reporter gene assays. An AP-1-dependent luciferase gene was transfected into Jurkat cells together with increasing amounts of Vav1 and/or PKCθ A/E expression vectors (Fig. 2 B). The slight induction of AP-1-dependent transcription mediated by Vav1 was strongly enhanced even by moderate amounts of coexpressed PKCθ A/E. These experiments revealed that the synergism also occurs at the level of DNA binding and gene expression.Figure 2Synergistic activation of AP-1 by Vav1 and PKC θ. A, Jurkat cells were transfected either with empty expression vector or with plasmids encoding Vav1 (10 μg) and/or PKCθ A/E (10 μg) at the indicated combinations. The next day, nuclear cell extracts were prepared, and the DNA binding activity of AP-1 was determined by EMSAs. An autoradiogram is displayed; the arrow indicates the location of the DNA-AP-1 complex, and the circle indicates the position of the unbound oligonucleotide. B, Jurkat cells were transiently transfected with 5 μg of an AP-1 luciferase reporter construct together with increasing amounts of PKCθ A/E and/or Vav1 at the indicated combinations. Luciferase activity was determined 30 h posttransfection. Gene expression is displayed as the average fold activation relative to vector-transfected cells. Mean values from three independent experiments are shown.View Large Image Figure ViewerDownload Hi-res image Download (PPT) JNK induces IL-2 promoter activity not only by targeting the AP-1 site but also via the CD28RE/AP composite element, which is bound by various proteins including members of the NF-κB/Rel and AP-1 families of transcription factors and so far only partially characterized proteins (27Shapiro V.S. Truitt K.E. Imboden J.B. Weiss A. Mol. Cell. Biol. 1997; 17: 4051-4058Crossref PubMed Scopus (178) Google Scholar, 31McGuire K.L. Iacobelli M. J. Immunol. 1997; 159: 1319-1327PubMed Google Scholar). Because the CD28RE/AP element is absolutely required for the transmission of CD28-derived signals on the IL-2 promoter (27Shapiro V.S. Truitt K.E. Imboden J.B. Weiss A. Mol. Cell. Biol. 1997; 17: 4051-4058Crossref PubMed Scopus (178) Google Scholar), we asked whether Vav1/PKCθ-mediated JNK activation also targets gene expression directed from this sequence element. A construct controlled by four repeats of the CD28RE/AP element fused to the luciferase reporter gene (4xRE/AP-Luc) was cotransfected with increasing amounts of Vav1 and/or PKCθ expression vectors (Fig.3 A). Both proteins cooperatively boosted CD28RE/AP-dependent transcription. To test whether the Vav1/PKCθ-derived JNK activity targets the CD28RE or the AP-1 half-site within the composite element, reporter constructs with mutations in either or both half-sites were tested for their inducibility. Mutation of either half-site completely prevented Vav1/PKCθ-mediated transcription (Fig. 3 B), revealing a strong interdependence of both half-sites. The effects of Vav1 and PKCθ on protein binding to the CD28RE/AP element were investigated by EMSAs using the labeled CD28RE/AP element (Fig. 3 C). Neither Vav1 nor PKCθ alone were able to induce DNA binding, but coexpression of both proteins caused DNA binding of transcription factors contained in the inducible DNA-protein complexes Ia and Ib. Formation of both complexes, which are known to contain predominantly c-Fos and c-Jun proteins (31McGuire K.L. Iacobelli M. J. Immunol. 1997; 159: 1319-1327PubMed Google Scholar), could be further triggered upon CD3/CD28 stimulation. In contrast to complex I, DNA-protein complexes II and III were already present in extracts from the untransfected, nonstimulated cells and showed no inducibility upon Vav1/PKCθ A/E coexpression and T-cell activation. The relatively moderate effects of Vav1/PKCθ on induced binding of proteins to the CD28RE/AP element can be attributed to the limited transfection efficiency of Jurkat cells. To investigate the relative importance of Vav1 and PKCθ for the CD3/CD28-mediated activation of JNK, the costimulation-induced activation of this mitogen-activated protein kinase was tested in the presence of DN versions of both signaling proteins. Coexpression of the kinase-deficient point mutant PKCθ K/R prevented JNK activation induced either by CD3/CD28 ligation or by treatment of cells with the pleiotropic PKC activator phorbol 12-myristate 13-acetate together with CD28 or the ionophore ionomycin (Fig.4 A). Similarly, two Vav1 variants with a mutation or a deletion in the Dbl homology domain (Vav1 LLL/QIF and Vav1Δ319–356), which is responsible for the activation of Rac, efficiently prevented CD3/CD28-triggered 32P incorporation into GST-c-Jun by JNK (Fig. 4 B). Vav1 and PKCθ are constitutively associated in unstimulated T-cells (18Kong Y.Y. Fischer K.D. Bachmann M.F. Mariathasan S. Kozieradzki I. Nghiem M.P. Bouchard D. Bernstein A. Ohashi P.S. Penninger J.M. J. Exp. Med. 1998; 188: 2099-2111Crossref PubMed Scopus (84) Google Scholar) but can also interact with a battery of further proteins, as revealed by various experimental approaches (9Bustelo X.R. Mol. Cell. Biol. 2000; 20: 1461-1477Crossref PubMed Scopus (446) Google Scholar, 32Meller N. Altman A. Isakov N. Stem Cells ( Basel ). 1998; 16: 178-192Crossref PubMed Scopus (54) Google Scholar). Whereas T-cell costimulation leads to the recruitment of Vav1 into an inducible multi-protein complex (10Hehner S.P. Hofmann T.G. Dienz O. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar), the association partners of Vav1 in unstimulated cells are not well characterized. To directly address this question, unstimulated Jurkat cells were lysed, and proteins contained in the lysates were separated according to size by gel filtration. The analysis of fractions for the distribution of Vav1 and PKCθ revealed an identical elution profile for both proteins, as revealed by Western blotting (Fig. 5 A). The two fractions (22 and 23) containing most of Vav1 and PKCθ correspond to a molecular mass of ∼170 kDa, suggesting that both proteins exist predominantly as heterodimers. Because previous studies showed that T-cell costimulation leads to the disruption of the Vav1/PKCθ heterodimer (4Dienz O. Hehner S.P. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 24547-24551Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar), we investigated the distribution of Vav1 and PKCθ in extracts from CD3/CD28-stimulated cells. These experiments revealed the majority of Vav1 in high molecular weight complexes of various sizes up to very large aggregates of more than 1 MDa (Fig. 5 B). In contrast, most of the PKCθ protein coeluted with the 158-kDa marker protein, and only a minor fraction was found in larger complexes (Fig.5 B). The signaling pathways were characterized by monitoring the effect of coexpressed DN forms of protein kinases from the JNK activation pathway on the activation signals derived from Vav1, PKCθ, or both (Fig.6 A). A kinase-dead form of MEKK1 affected Vav1-mediated AP-1 activity only moderately but significantly inhibited PKCθ- and PKCθ/Vav1-generated signals. A comparison between DN forms of the JNKKs MKK4 and MKK7 revealed that Vav1-derived activation signals were only moderately blocked by expression of DN forms of each of these kinases. In contrast, simultaneous expression of kinase-inactive forms of MKK4 and MKK7 completely prevented Vav1-mediated AP-1 activation, indicating that both kinases can mutually compensate the functions of each other. PKCθ- and Vav1/PKCθ-derived signals were only partially impaired in the presence of DN MKK4 but efficiently blocked by MKK7 K/L, indicating the special importance of MKK7 for this pathway. We also tested the impact of pathway-specific inhibitory compounds on Vav1- and/or PKCθ-induced AP-1-dependent transcription (Fig. 6 B). Vav1-derived signaling, but not PKCθ- and Vav1/PKCθ-mediated AP-1 activation, was preferentially inhibited by cyclosporin A, a compound that blocks the Ca2+-dependent activation of the phosphatase calcineurin. The PKC inhibitor bisindolylmaleimide blocked Vav1- and PKCθ-mediated AP-1 activity, raising the possibility that Vav1 acts upstream from PKCθ. To address this question directly, Jurkat cells were transfected with various combinations of active and inactive variants of Vav1 and PKCθ prior to stimulation with αCD3/αCD28 antibodies and subsequent analysis of JNK activity. Vav1-induced JNK activation was efficiently prevented by kinase-dead PKCθ K/R, but PKCθ A/E-mediated JNK activation was not affected by DN Vav1 LLL/QIF (Fig. 7 A). To investigate whether directional signaling also occurs at the level of AP-1-dependent transcription, an analogous experimental approach was taken by monitoring AP-1-dependent luciferase activity. Similarly, Vav1-induced transcription of the AP-1-dependent luciferase gene was inhibited upon coexpression of PKCθ K/R (Fig. 7 B) or the PKC inhibitor bisindolylmaleimide (data not shown). In contrast, gene activation induced by PKCθ A/E was not affected by the DN Vav1 variant Vav1Δ319–356. In summary, these data clearly indicate that PKCθ acts downstream from Vav1 in a pathway leading to the activation of JNK. Here we show that Vav1 and PKCθ synergize for the induction of JNK. Because these two proteins also cooperate for the up-regulation of NF-κB, the simultaneous activation of several pathways may be important for the efficient transcription of target genes, because many promoters (e.g. the IL-2 and IL-4 promoter) depend on the coordinated activation of several transcription factors. Interestingly, PKCθ does not only synergize with Vav1 (this study) but also with calcineurin for the activation of JNK (22Werlen G. Jacinto E. Xia Y. Karin M. EMBO J. 1998; 17: 3101-3111Crossref PubMed Scopus (252) Google Scholar). The Vav1 protein cooperates with SLP-76 and Syk family kinases for the activation of IL-2 transcription and nuclear factor of activated T-cells activation, respectively (33Wu J. Motto D.G. Koretzky G.A. Weiss A. Immunity. 1996; 4: 593-602Abstract Full Text Full Text PDF PubMed Scopus (299) Google Scholar, 34Deckert M. Tartare Deckert S. Couture C. Mustelin T. Altman A. Immunity. 1996; 5: 591-604Abstract Full Text PDF PubMed Scopus (245) Google Scholar). One could speculate that the synergistic behavior of signaling proteins for the initiation of T-cell signaling pathways may be an important regulatory principle, especially early in infection when only low doses of antigen are present, but an efficient cellular response is required. In that respect it will be interesting to analyze signaling pathways and the immune response in Vav1/PKCθ double knockout mice in future experiments. In this study we show that at least the abundant fraction of PKCθ and Vav1 proteins is present as heterodimers in unstimulated cells under the conditions used here. Given the importance of both proteins for the initiation of various signaling pathways (10Hehner S.P. Hofmann T.G. Dienz O. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar, 32Meller N. Altman A. Isakov N. Stem Cells ( Basel ). 1998; 16: 178-192Crossref PubMed Scopus (54) Google Scholar) and the necessity to keep activation pathways in nonstimulated T-cells silent (35Rudd C.E. Schneider H. Curr. Biol. 2000; 10: R344-R347Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar, 36Sosinowski T. Pandey A. Dixit V.M. Weiss A. J. Exp. Med. 2000; 191: 463-474Crossref PubMed Scopus (96) Google Scholar), this heterodimerization might serve the purpose of keeping both proteins in an inactive state. T-cell activation leads to the transient dissociation of Vav1 and PKCθ by an unknown mechanism (4Dienz O. Hehner S.P. Dröge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 24547-24551Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar) and the incorporation of Vav1 into temporally regulated and highly dynamic and semi-stable multi-protein signaling complexes (37Pacini S. Valensin S. Telford J.L. Ladbury J. Baldari C.T. Eur. J. Immunol. 2000; 30: 2620-2631Crossref PubMed Scopus (15) Google Scholar). Under the conditions used here, only a minor fraction of the PKCθ protein is incorporated into high molecular weight complexes in stimulated T-cells. It will be interesting to investigate the composition, stability, and spatial and temporal regulation of these multi-protein complexes. Our results indicate that Vav1 is located upstream from PKCθ in the JNK activation cascade. This finding is in good agreement with a previous study that demonstrated a Vav1-dependent membrane and cytoskeleton translocation of PKCθ (20Villalba M. Coudronniere N. Deckert M. Teixero E. Mas P. Altman A. Immunity. 2000; 12: 151-160Abstract Full Text Full Text PDF PubMed Scopus (199) Google Scholar). The same study shows that the effects of Vav1 on PKCθ are mediated by Vav1-induced actin polymerization and cytoskeletal reorganization. Biochemical and genetic evidence suggests that Vav1 exerts its function by at least two mechanisms. One pathway leads to the release of Ca2+ and the subsequent activation of the serine phosphatase calcineurin, which stimulates nuclear entry and transactivation of transcription factor nuclear factor of activated T-cells. This pathway is independent from the GDP/GTP exchange factor function of Vav1 (38Kuhne M.R. Ku G. Weiss A. J. Biol. Chem. 2000; 275: 2185-2190Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar) and cannot be inhibited by the regulatory protein Cbl-b (39Krawczyk C. Bachmaier K. Sasaki T. Jones R.G. Snapper S.B. Bouchard D. Kozieradzki I. Ohashi P.S. Alt F.W. Penninger J.M. Immunity. 2000; 13: 463-473Abstract Full Text Full Text PDF PubMed Scopus (185) Google Scholar). The second pathway is Ca2+-independent, can be inhibited by Cbl-b, and relies on the GDP/GTP exchange factor function of Vav1, thus leading to actin polymerization, cytoskeletal reorganization, and further processes (39Krawczyk C. Bachmaier K. Sasaki T. Jones R.G. Snapper S.B. Bouchard D. Kozieradzki I. Ohashi P.S. Alt F.W. Penninger J.M. Immunity. 2000; 13: 463-473Abstract Full Text Full Text PDF PubMed Scopus (185) Google Scholar). We favor a model where Vav1 and PKCθ activate JNK via overlapping and distinct pathways. The PKCθ-derived signals are Ca2+-independent and cannot be inhibited by calcineurin, because PKCθ is located downstream from it. Accordingly, a DN form of PKCθ inhibits JNK activation mediated by ionomycin, which causes the release of intracellular Ca2+ (compare Fig. 4 A). Similarly, the pathway shared by both signaling proteins and mediating the synergistic activation of JNK is Ca2+/calcineurin-independent. In contrast, the Vav1-mediated JNK activation pathway contains a Ca2+-dependent component that can be inhibited by cyclosporin A. This model would also explain earlier results that showed only moderate JNK activation by phorbol 12-myristate 13-acetate and ionomycin alone, whereas the simultaneous administration of both compounds strongly activated JNK activity (23Ghaffari-Tabrizi N. Bauer B. Villunger A. Baier-Bitterlich G. Altman A. Utermann G. Uberall F. Baier G. Eur. J. Immunol. 1999; 29: 132-142Crossref PubMed Scopus (108) Google Scholar). This study suggests that Vav1-derived signals target MKK4 and MKK7. In contrast, PKCθ- and Vav1/PKCθ-derived signals are transmitted preferentially via MKK7, which seems to be of special relevance for this pathway. The importance of MKK4 for the CD3/CD28-induced activation of JNK is still not clear. One group describes a defective JNK activation in thymocytes obtained from MKK4-deficient mice but normal JNK activation in peripheral T-cells (40Nishina H. Bachmann M. Oliveira dos Santos A.J. Kozieradzki I. Fischer K.D. Odermatt B. Wakeham A. Shahinian A. Takimoto H. Bernstein A. Mak T.W. Woodgett J.R. Ohashi P.S. Penninger J.M. J. Exp. Med. 1997; 186: 941-953Crossref PubMed Scopus (116) Google Scholar). Another study demonstrates normal activation of JNK in response to CD3/CD28 stimulation in lymph node cell suspensions from MKK4−/− mice (41Swat W. Fujikawa K. Ganiatsas S. Yang D. Xavier R.J. Harris N.L. Davidson L. Ferrini R. Davis R.J. Labow M.A. Flavell R.A. Zon L.I. Alt F.W. Immunity. 1998; 8: 625-634Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar). Further studies are required to resolve these differences, which may also depend on the developmental stage of the lymphocytes and the cell types studied. In accordance with the predominant role of MKK7 described here, peripheral T-cells from mice lacking MKK7 show only low levels of JNK activity after CD3/CD28 stimulation (15Dong C. Yang D.D. Tournier C. Whitmarsh A.J. Xu J. Davis R.J. Flavell R.A. Nature. 2000; 405: 91-94Crossref PubMed Scopus (284) Google Scholar). The PKCθ-mediated signaling pathways are only incompletely understood. Furthermore, it is currently not known whether the competence of PKCθ to deliver activation signals is controlled by its intracellular localization, interaction with binding partners, or both. Because overexpression of the PKCθ-interacting protein, PKC-interacting cousin of thioredoxin, inhibits PKCθ-mediated activation of JNK and NF-κB (42Witte S. Villalba M. Bi K. Liu Y. Isakov N. Altman A. J. Biol. Chem. 2000; 275: 1902-1909Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar), this protein seems to be involved in the first signaling step prior to the separation of the two signaling pathways. Given the importance of PKCθ for the activation of NF-κB and JNK, selective inhibition of this kinase might be a useful strategy to interfere with several activation pathways and thereby modulate T-cell costimulatory signals in inflammatory diseases. We are grateful to Dr. Stephan Urban (Heidelberg) for help with gel filtration, Dr. Susanne Bacher and Ingrid Fryson for helpful comments on the manuscript, Tarik Hamid for technical assistance, and colleagues who generously provided plasmids." @default.
• W2028656867 created "2016-06-24" @default.
• W2028656867 creator A5003211694 @default.
• W2028656867 creator A5032812506 @default.
• W2028656867 creator A5037394787 @default.
• W2028656867 creator A5038809023 @default.
• W2028656867 creator A5089889861 @default.
• W2028656867 date "2001-01-01" @default.
• W2028656867 modified "2023-09-30" @default.
• W2028656867 title "Protein Kinase C θ Cooperates with Vav1 to Induce JNK Activity in T-cells" @default.
• W2028656867 cites W1973614704 @default.
• W2028656867 cites W1983329536 @default.
• W2028656867 cites W1985272248 @default.
• W2028656867 cites W1989142268 @default.
• W2028656867 cites W1989342624 @default.
• W2028656867 cites W1992555403 @default.
• W2028656867 cites W1998487776 @default.
• W2028656867 cites W2001234795 @default.
• W2028656867 cites W2003319634 @default.
• W2028656867 cites W2003976708 @default.
• W2028656867 cites W2006413140 @default.
• W2028656867 cites W2007986629 @default.
• W2028656867 cites W2013592169 @default.
• W2028656867 cites W2016198472 @default.
• W2028656867 cites W2018088003 @default.
• W2028656867 cites W2039970092 @default.
• W2028656867 cites W2042584344 @default.
• W2028656867 cites W2044356299 @default.
• W2028656867 cites W2046860197 @default.
• W2028656867 cites W2051320355 @default.
• W2028656867 cites W2054419682 @default.
• W2028656867 cites W2058588605 @default.
• W2028656867 cites W2058811157 @default.
• W2028656867 cites W2070330987 @default.
• W2028656867 cites W2076485183 @default.
• W2028656867 cites W2078554854 @default.
• W2028656867 cites W2078566133 @default.
• W2028656867 cites W2084243642 @default.
• W2028656867 cites W2099764547 @default.
• W2028656867 cites W2111910803 @default.
• W2028656867 cites W2118367937 @default.
• W2028656867 cites W2122353285 @default.
• W2028656867 cites W2125449081 @default.
• W2028656867 cites W2129896296 @default.
• W2028656867 cites W2138412906 @default.
• W2028656867 cites W2144711633 @default.
• W2028656867 cites W2165039877 @default.
• W2028656867 cites W2170680089 @default.
• W2028656867 cites W4231579254 @default.
• W2028656867 doi "https://doi.org/10.1074/jbc.m011139200" @default.
• W2028656867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11274147" @default.
• W2028656867 hasPublicationYear "2001" @default.
• W2028656867 type Work @default.
• W2028656867 sameAs 2028656867 @default.
• W2028656867 citedByCount "28" @default.
• W2028656867 countsByYear W20286568672013 @default.
• W2028656867 countsByYear W20286568672017 @default.
• W2028656867 countsByYear W20286568672019 @default.
• W2028656867 countsByYear W20286568672021 @default.
• W2028656867 crossrefType "journal-article" @default.
• W2028656867 hasAuthorship W2028656867A5003211694 @default.
• W2028656867 hasAuthorship W2028656867A5032812506 @default.
• W2028656867 hasAuthorship W2028656867A5037394787 @default.
• W2028656867 hasAuthorship W2028656867A5038809023 @default.
• W2028656867 hasAuthorship W2028656867A5089889861 @default.
• W2028656867 hasBestOaLocation W20286568671 @default.
• W2028656867 hasConcept C184235292 @default.
• W2028656867 hasConcept C185592680 @default.
• W2028656867 hasConcept C86803240 @default.
• W2028656867 hasConcept C95444343 @default.
• W2028656867 hasConcept C97029542 @default.
• W2028656867 hasConceptScore W2028656867C184235292 @default.
• W2028656867 hasConceptScore W2028656867C185592680 @default.
• W2028656867 hasConceptScore W2028656867C86803240 @default.
• W2028656867 hasConceptScore W2028656867C95444343 @default.
• W2028656867 hasConceptScore W2028656867C97029542 @default.
• W2028656867 hasIssue "23" @default.
• W2028656867 hasLocation W20286568671 @default.
• W2028656867 hasOpenAccess W2028656867 @default.
• W2028656867 hasPrimaryLocation W20286568671 @default.
• W2028656867 hasRelatedWork W1698057790 @default.
• W2028656867 hasRelatedWork W2004726042 @default.
• W2028656867 hasRelatedWork W2022630818 @default.
• W2028656867 hasRelatedWork W2025794474 @default.
• W2028656867 hasRelatedWork W2063716351 @default.
• W2028656867 hasRelatedWork W2070816084 @default.
• W2028656867 hasRelatedWork W2081289502 @default.
• W2028656867 hasRelatedWork W2170617996 @default.
• W2028656867 hasRelatedWork W2529122668 @default.
• W2028656867 hasRelatedWork W3013907891 @default.
• W2028656867 hasVolume "276" @default.
• W2028656867 isParatext "false" @default.
• W2028656867 isRetracted "false" @default.
• W2028656867 magId "2028656867" @default.
• W2028656867 workType "article" @default.